• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Forma Therapeutics Holdings Inc.

    10/24/22 11:22:28 AM ET
    $FMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FMTX alert in real time by email
    15-12G 1 d357084d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-39333

     

     

    Forma Therapeutics Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    300 North Beacon Street

    Suite 501

    Watertown, Massachusetts 02472

    (617) 679-1970

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

       ☒  

    Rule 12g-4(a)(2)

       ☐  

    Rule 12h-3(b)(1)(i)

       ☒  

    Rule 12h-3(b)(1)(ii)

       ☐  

    Rule 15d-6

       ☐  

    Rule 15d-22(b)

       ☐  

    Approximate number of holders of record as of the certification or notice date: one (1).

    Pursuant to the requirements of the Securities Exchange Act of 1934, Forma Therapeutics Holdings, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: October 24, 2022
        FORMA THERAPEUTICS HOLDINGS, INC.
        By:  

    /s/ Ulrich Christian Otte

        Name:   Ulrich Christian Otte
        Title:   President

     

     

     

    Get the next $FMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FMTX

    DatePrice TargetRatingAnalyst
    6/13/2022$46.00 → $21.00Overweight
    Cantor Fitzgerald
    11/12/2021$54.00 → $40.00Outperform
    SVB Leerink
    8/17/2021$55.00 → $53.00Buy
    HC Wainwright & Co.
    8/2/2021$58.00Buy
    Craig Hallum
    More analyst ratings

    $FMTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Forma Therapeutics Holdings Inc.

      15-12G - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/24/22 11:22:28 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Forma Therapeutics Holdings Inc.

      EFFECT - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/18/22 12:15:07 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.

      S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/14/22 9:27:29 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Forma Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Forma Therapeutics with a rating of Overweight and set a new price target of $21.00 from $46.00 previously

      6/13/22 7:18:38 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Forma Therapeutics Hldgs with a new price target

      SVB Leerink reiterated coverage of Forma Therapeutics Hldgs with a rating of Outperform and set a new price target of $40.00 from $54.00 previously

      11/12/21 1:07:48 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Forma Therapeutics Hldgs with a new price target

      HC Wainwright & Co. reiterated coverage of Forma Therapeutics Hldgs with a rating of Buy and set a new price target of $53.00 from $55.00 previously

      8/17/21 6:25:41 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care